Telix Pharmaceuticals Limited (TLX.AX)
Develops radioactive drugs that target and treat cancers like prostate and kidney cancer.
14.50+0.00%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago-28.0%
The outlook
Telix Pharmaceuticals is trading at $14.50 with strong analyst support—the average target sits roughly 62% above the current price. The stock sits in the middle of its 52-week range and shows mixed momentum against short-term moving averages, though analyst consensus leans notably bullish.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 13 analysts
Price trendMixed vs its moving averages
52-week range48% of the way from its 52-week low to high
Price targetAvg target +62% vs current price
Analyst price target
~12-month · 13 analysts23.48average target+61.9% vs now
Now 14.50
Low 18.00High 31.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$4.91B
52-wk high
21.21
52-wk low
8.26
50-day avg
14.72
200-day avg
13.35
Trailing P/E
—